EMERGENCT07861152
Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD)
StatusNot Yet Recruiting
PhasePhase 1
SponsorRegeneron Pharmaceuticals
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Timeframe: Up to approximately 68 weeks
Secondary (7)
Concentrations of REGN24493 in serum
Serum Thyroid-Stimulating Hormone (TSH) levels
Serum free T4 (fT4) levels
Serum free T3 (fT3) levels
Serum total T3 (TT3) levels
Show 2 moreShow less
Occurrence of anti-drug antibody (ADA) to REGN24493 in serum
Magnitude of anti-drug antibody (ADA) to REGN24493 in serum
Arms and interventions
Dose EscalationExperimental
Placebo ComparatorPlacebo comparator
Drugs: REGN24493, Placebo